Condition: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) · Sponsor: Innoviva Specialty Therapeutics
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
This description comes directly from the study's public registry record.
ISTX Clinical Trials · 617-715-3600 · Clinicaltrials@istx.com
Always discuss trial participation with your own doctor first.
| UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| ECU Brody School of Medicine | Greenville, North Carolina, United States | Recruiting |
| University of Texas Medical Branch at Galveston | Galveston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06801223